Table 4.
Study | Design | No. of# patients | Received treatment (technique, dose, volumes and associated treatments) | Follow up(months) | Outcomes/Endpointdefinition | Evaluation method | Predictive factors identified in multivariate analysis |
---|---|---|---|---|---|---|---|
Peeters et al. (16) | Multicenter phase 3 RCT | 641 |
|
44 | Grade ≥ 2 rectal bleeding, requiring treatment by laser coagulation and/or blood transfusion | Modified RTOG/EORTC score | 1. Acute GIT (HR=1.9; p ≤ 0.01) 2. GI symptoms prior to radiotherapy 2. No association found with dosimetric parameters (HR=6.4; p ≤ 0.01) |
Ebert et al. (27) | Multicenter phase 3 RCT | 754 |
|
72 | Prevalence of peak toxicity grade at 36 months |
SOMAT LENT and CTCAE V2.0 | 1. No predictive factors identified |
Schaake et al. (30) | Prospective cohort | 262 |
|
> 36 months | Prevalence grade ≥2 toxicities after 36 months | CTCAE V3.0 and patient questionnaire |
1. No clinical or dosimetric correlation with rectal pain |
Thor et al. (29) | Prospective cohorts | 212 in the Danish cohort 277 in the Swedish cohort |
|
42 months for the Danish cohort 76 months for the Swedish cohort |
Prevalence of moderately severe symptoms (occurring at least once/week) and the use of diapers/pads |
Questionnaires specific to the Danish and Swedish cohorts | 1. HT, tobacco and V15 Gy are predictive of pain |
RCT, randomized controlled trial; 3D, tridimensional radiotherapy; RT, radiotherapy; CTV, clinical target volume; PTV, planning target volume; SV, seminal vesicles; HT, hormonotherapy; GIT, gastrointestinal toxicities; OR, odds ratio; HR, hazard ratio.